Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions

Clinical Biochemistry

Volumn 44, Issue 2-3, 2011, Pages 216-220

  Xie, Li ^a,b   Wang, Tingting ^a,b   Yu, Shaorong ^a,b   Chen, Xi ^b   Wang, Lifeng ^a,b   Qian, Xiaoping ^a,b   Yu, Lixia ^a,b   Ding, Yitao ^a   Zhang, Chenyu ^b   Liu, Baorui ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Cell free miRNAs; Diagnosis; Malignant effusions; MiR 24; MiR 30d

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 24; MICRORNA 30D; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; ASCITES; BENIGN TUMOR; CELL FREE SYSTEM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SAMPLING; UPREGULATION; GENETICS; PLEURAL EFFUSION, MALIGNANT;

ASCITES; BIOMARKERS, TUMOR; MICRORNAS; PLEURAL EFFUSION, MALIGNANT; UP-REGULATION;

EID: 79151477033     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.11.002     Document Type: Article

References (25)

1. Lee J.H., Hong Y.S., Ryu J.S., Chang J.H. p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer 2004, 44:33-42.
2. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000, 162:1987-2001.
3. Lyons-Boudreaux V., Mody D.R., Zhai J., Coffey D. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 2008, 132:23-28.
4. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
5. Leelawat K., Leelawat S., Ratanachu-Ek T., Trubwongchareon S., Wannaprasert J., Tripongkaruna S., et al. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol 2006, 12:4195-4198.
6. Wong S.C., Lo S.F., Cheung M.T., Ng K.O., Tse C.W., Lai B.S., et al. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res 2004, 10:1613-1617.
7. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27:5848-5856.
8. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz V, Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
9. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010, 127:118-126.
10. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
11. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
12. Yao J., Liang L., Huang S., Ding J., Tan N., Zhao Y., et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010, 51:846-856.
13. Wang T., Qian X., Wang Z., Wang L., Yu L., Ding Y., et al. Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer 2009, 125:1921-1925.
14. Chow T.F., Youssef Y.M., Lianidou E., Romaschin A.D., Honey R.J., Stewart R., et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158.
15. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
16. Kuralay F., Tokgoz Z., Comlekci A. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 2000, 300:43-55.
17. Shu J., Sun G.Y., Liu A.P., Liu J. Diagnostic accuracy of human telomerase reverse transcriptase mRNA in malignant pleural effusions: a preliminary report for in situ hybridization detection. Clin Chim Acta 2007, 381:131-135.
18. Hurst D.R., Edmonds M.D., Welch D.R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009, 69:7495-7498.
19. Lal A., Pan Y., Navarro F., Dykxhoorn D.M., Moreau L., Meire E., et al. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat StruCq Mol Biol 2009, 16:492-498.
20. Lal A., Navarro F., Maher C.A., Maliszewski L.E., Yan N., O'Day E., et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 2009, 35:610-625.
21. Takagi S., Nakajima M., Kida K., Yamaura Y., Fukami T., Yokoi T. MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. J Biol Chem 2010, 285:4415-4422.
22. Mishra P.J., Song B., Mishra P.J., Wang Y., Humeniuk R., Banerjee D., et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS ONE 2009, 4:e8445.
23. Marton S., Garcia M.R., Robello C., Persson H., Trajtenberg F., Pritsch O., et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008, 22:330-338.
24. Visone R., Pallante P., Vecchione A., Cirombella R., Ferracin M., Ferraro A., et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007, 26:7590-7595.
25. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.